Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Plates from Vesalius' Fabrica showing arteries and veins.
Plates 44 (veins) and 45 (arteries) of Vesalius' Fabrica

Professor Ellie Tzima has been awarded a highly competitive European Research Council (ERC) Synergy Grant to investigate the enigmatic neurovascular interface of peripheral nerves – a critical but poorly understood junction between the nervous and vascular systems.

The University of Oxford team will collaborate with three leading European scientists: Dr Dario Bonanomi, a neuroscientist at Ospedale San Raffaele in Italy; Dr Isabelle Brunet, a vascular biologist at the Collège de France; and Dr Tambet Teesalu, a nanoscientist at the University of Tartu in Estonia. Together, this international consortium will combine complementary expertise in neuroscience, vascular biology, and nanotechnology to unravel the mechanisms that coordinate communication between nerves and blood vessels.

The neurovascular interface is one of the least understood frontiers in human biology. We are only just beginning to appreciate how closely blood vessels and nerves communicate in order to maintain tissue health. This ERC Synergy Grant provides an exceptional opportunity to bring together diverse expertise and resources across Europe to understand how these systems interact and what happens when that dialogue breaks down.
- Professor Ellie Tzima

The Oxford component of the project will focus on the cells which form the inner lining of blood and lymphatic vessels (endothelial cells), how they sense and respond to mechanical forces, and the role that this plays in the neurovascular interface. Professor Tzima's group will combine molecular, biophysical and imaging approaches to explore how these mechanical cues regulate nerve–vessel interactions. They will investigate how the disruption of these interactions may contribute to peripheral neuropathies, a group of debilitating conditions that affect millions of people worldwide.

The new consortium will establish a cross-disciplinary network at the interface of neurobiology, vascular science, and mechanobiology, aiming to generate insights that could open new therapeutic avenues for neurovascular and neuromuscular disorders.

ERC Synergy Grants support small teams of leading investigators addressing ambitious scientific questions that cannot be tackled by a single group. It is one of the most prestigious and competitive funding awards in Europe. This year, 712 proposals were submitted and one in ten were selected for funding.

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.